AIFF

Firefly Neuroscience, Inc. Common Stock

AIFF

Market cap $37.1M

Overview Fund Activity

2.77 USD

-0.08

2.81%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

2.78

+0.01

0.36%

1 day

-2.81%

5 days

4.53%

1 month

0.73%

3 months

-9.48%

6 months

-47.04%

Year to date

8.2%

1 year

-25.34%

5 years

-96.91%

10 years

-96.91%

About: Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.

Employees: 13

Technology Software - Application

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

16% more funds holding

Funds holding: 19 [Q1] → 22 (+3) [Q2]

5% more capital invested

Capital invested by funds: $1.69M [Q1] → $1.77M (+$83.1K) [Q2]

0.44% less ownership

Funds ownership: 5.32% [Q1] → 4.87% (-0.44%) [Q2]

See Fund Rankings

Financial journalist opinion

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS).

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR' Platform

– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to unveil its new ‘CLEAR' (CLeaning EEG ARtifacts) Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled electroencephalogram (EEG) data quality.

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR' Platform

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly's commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof.

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

Firefly Neuroscience to be Added to the Russell Microcap® Index

– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap® Index as part of this year's reconstitution.

Firefly Neuroscience to be Added to the Russell Microcap® Index

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer's Patients

– R esearch supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia –

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer's Patients

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors' earn-out is in Firefly's common stock. The complete corrected press release follows:

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. (“Evoke”), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health.

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the "Phase 1").

Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

Extends cash runway well into mid-2026; no new/replacement warrants issued Extends cash runway well into mid-2026; no new/replacement warrants issued

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

Firefly Neuroscience Accepted into NVIDIA Connect Program

Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform

Firefly Neuroscience Accepted into NVIDIA Connect Program

See News Rankings

Charts implemented using Lightweight Charts™